Trial Profile
A Multi-centre, Open-label, Single-arm, Dose-finding Phase I/II Study to Evaluate Safety, Tolerability, Dosing Schedule, and Preliminary Efficacy of Carrier-added 4-L-[131I]Iodo-phenylalanine (131I-IPA), Administered as Single or Repetitive Injections in Patients With Recurrent Glioblastoma Multiforme (GBM), Concomitantly to 2nd Line External Radiation Therapy (XRT) - IPAX- 1
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 29 Mar 2024
Price :
$35
*
At a glance
- Drugs ACD 101 (Primary)
- Indications Glioblastoma
- Focus Adverse reactions
- Acronyms 131I-IPA + XRT in recurrent GBM; IPAX-1
- Sponsors Telix Pharmaceuticals
- 12 Apr 2023 Status changed from active, no longer recruiting to completed.
- 20 Sep 2022 Final results published in the Telix Pharmaceuticals Media Release.
- 28 Jul 2022 This trial has been completed in Netherlands (Date of the global end of the trial : 31-May-2022), according to European Clinical Trials Database record.